פרופ' יגאל דניאל [דני] כהן

אמריטוס בביה"ס לבריאות הציבור
ועדת מינויים יחידתית בדיקאנט ומנהל הפקולטה לרפואה
ועדת מינויים יחידתית בביה"ס לבריאות הציבור
ביה"ס לבריאות הציבור אמריטוס
ניווט מהיר:
פרופ' יגאל דניאל [דני] כהן
טלפון פנימי: 03-6407081
פקס: 03-6409868
אתר אישי

Positions

Daniel (Dani) I. Cohen MPH, PhD

Professor of Epidemiology and Preventive Medicine, School of Public Health

Former Head of the School of Public Health

Co-Founder and Director, Summer Institute of Advanced Epidemiology & Preventive Medicine

Head, Tiberio Swartz Research Forum on Epidemiology of Infectious Diseases and Biosecurity

Biography

Professor Daniel (Dani) Cohen joined Tel Aviv University (TAU) for a full-time academic position in 2002 and has been a full Professor since 2007. Previously, he served in the Israel Defense Forces for many years and was the Director of the Infectious Diseases Research Institute in the Medical Corps. Prof. Cohen served as the Head of Tel Aviv University School of Public Health for 6 years, after 4 years as Chair of the Department of Epidemiology and Preventive Medicine. Between 2017 and 2021, he served as an elected member of the Executive Committee of Tel Aviv University Senate.

Prof. Cohen has been the Diana & Stanley Steyer Chair of Cancer Prevention and Control (2009-2024) and the Director of the Stanley Steyer Institute for Cancer Epidemiology and Research (2009-2018).

Prof. Cohen founded the Tiberio Swartz Forum on Epidemiology of Infectious Diseases and Biosecurity, a very active national and international stage for scientific communications and discussions in the field of infectious diseases and vaccines. Additionally, he is the co-founder and director of the Summer International Institute of Advanced Epidemiology and Preventive Medicine at TAU School of Public Health and co-founder of the Master of Public Health Program at the School of Medicine, Copperbelt University, Zambia. He also serves as an executive board member and the current Chairperson of the Middle East Consortium for Infectious Diseases Surveillance (MECIDS) and acts on various national and international advisory boards in the field of infectious diseases and vaccines. Prof. Cohen has been a consultant for the World Health Organization (WHO) on many occasions. In November 2020, he was appointed to the WHO Technical Advisory Group on candidate vaccine prioritization (TAG-CVP).

Prof. Cohen and his research lab at the TAU School of Public Health focus on the development and evaluation of enteric vaccines, with a particular emphasis on Shigella vaccines. Prof. Cohen and his team's research has been funded over the years by numerous competitive grants.

Prof. Cohen has supervised many graduate and post-graduate students. He has received several awards for his outstanding contribution to research and has authored over 280 peer-reviewed articles.

 

 

Research Interests

  • Epidemiology of infectious diseases
  • Vaccinology
  • Development and evaluation of enteric vaccines
  • Risk and protective host factors associated with enteric diseases and in particular: shigellosis
  • Study of the association between selected infectious agents (e.g. Helicobacter pylori, Human Papilloma Virus) and cancer 

 

Selected Publications

Selected publications

 

Click here for a complete list of Prof. Cohen's Peer-Reviewed Articles

Publications (from 2022, the last three years)

  1. MacLennan CA, Talaat KR, Kaminski RW, Cohen D, Riddle MS, Giersing BK. Critical needs in advancing Shigella vaccines for global health. The Journal of Infectious Diseases. 2022;225(9):1500-3.
  2. Chodick G, Tene L, Rotem RS, Patalon T, Gazit S, Ben-Tov A, Weil C, Goldshtein I, Twig G, Cohen D, Muhsen K. The effectiveness of the Two-Dose BNT162b2 vaccine: analysis of real-world data. Clin Infect Dis. 2022;74(3):472-8
  3. Izak M, Gendelman V, Bransburg-Zabary S, Stoyanov E, Gat R, Cohen D, Chen J, Maor Y, Benov A, Lev B, Zimhony O, Shinar E. Qualifying coronavirus disease 2019 convalescent plasma donors in Israel. Vox Sang. 2022;117(2):185-92.
  4. Yahalom-Ronen Y, Erez N, Fisher M, Tamir H, Politi B, Achdout H, Melamed S, Glinert I, Weiss S, Cohen-Gihon I, Israeli O…,Cohen D,…Paran N. Neutralization of SARS-CoV-2 variants by rVSV-ΔG-spike-elicited human sera. Vaccines. 2022;10(2):291.
  5. Mathur S, Banai M, Cohen D. Natural Brucella melitensis Infection and Rev. 1 Vaccination Induce Specific Brucella O-Polysaccharide Antibodies Involved in Complement Mediated Brucella Cell Killing. Vaccines. 2022;10(2):317.
  6. Edelman-Klapper H, Zittan E, Shitrit AB, Rabinowitz KM, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y…Cohen D, Dotan I, REsponses to COVid-19 vaccinE IsRaeli IBD group (RECOVER). Lower serologic response to COVID-19 mRNA vaccine in patients with inflammatory bowel diseases treated with anti-TNFα. Gastroenterology. 2022;162(2):454-67.
  7. Gazit S, Shlezinger R, Perez G, Lotan R, Peretz A, Ben-Tov A, Herzel E, Alapi H, Cohen D, Muhsen K, Chodick G, Patalon T. The Incidence of SARS-CoV-2 Reinfection in Persons With Naturally Acquired Immunity With and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine: A Retrospective Cohort Study. Annals of Internal Medicine. 2022;175(5):674-81.
  1. Lapidot Y, Reshef L, Maya M, Cohen D, Gophna U, Muhsen K. Socioeconomic disparities and household crowding in association with the fecal microbiome of school-age children. NPJ biofilms and microbiomes. 2022;8(1):1-2.
  1. Gazit S, Shlezinger R, Perez G, Lotan R, Peretz A, Ben-Tov A, Herzel E, Alapi H, Cohen D, Muhsen K, Chodick G, Patalon T. SARS-CoV-2 Naturally Acquired Immunity vs. Vaccine-induced Immunity, Reinfections versus Breakthrough Infections: a Retrospective Cohort Study. Clinical Infectious Diseases. 2022;75(1):e545-e551.
  2. Bassal R, Shohat T, Levin T, Pando R, Shinar E, Amichay D, Barak M, Ben-Dor A, Bar-Haim A, Mendelson E, Cohen D, Keinan-Boker L, Indenbaum V. The Concordance between Mumps and Rubella Sero-Positivity among the Israeli Population in 2015. Vaccines. 2022;10(7):996.
  1. Muhsen K, Maimon N, Mizrahi A, Bodenheimer O, Cohen D, Maimon M, Grotto I, Dagan R. Effectiveness of BNT162b2 mRNA coronavirus disease 2019 (covid-19) vaccine against acquisition of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among healthcare workers in long-term care facilities: a prospective cohort study. Clinical Infectious Diseases. 2022;75(1):e755-63.
  2. Rabinowitz KM, Navon M, Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H...Cohen D,..on behalf of the Responses to COVID-19 Vaccine Israeli IBD Group. Anti-TNFα Treatment Impairs Long-Term Immune Responses to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases. Vaccines. 2022;10(8):1186.
  3. Meron-Sudai S, Reizis A, Goren S, Bialik A, Hochberg A, Cohen D. Pentraxin 3 and Shigella LPS and IpaB Antibodies Interplay to Defeat Shigellosis. Journal of Clinical Medicine. 2022;11(15):4384.
  4. Muhsen K, Maimon N, Mizrahi AY, Varticovschi B, Bodenheimer O, Cohen D, Dagan R. Association of BNT162b2 Vaccine Third Dose Receipt With Incidence of SARS-CoV-2 Infection, COVID-19–Related Hospitalization, and Death Among Residents of Long-term Care Facilities, August to October 2021. JAMA Network Open. 2022;5(7):e2219940.
  5. Muhsen K, Maimon N, Mizrahi AY, Boltyansky B, Bodenheimer O, Diamant ZH, Gaon L, Cohen D, Dagan R. Association of receipt of the fourth BNT162b2 dose with omicron infection and COVID-19 hospitalizations among residents of long-term care facilities. JAMA Internal Medicine. 2022;182(8):859-67.
  6. Cohen D, Ashkenazi S, Schneerson R, Farzam N, Bialik A, Meron-Sudai S, Asato V, Goren S, Baran TZ, Muhsen K, Gilbert PB, MacLennan CA. Threshold protective levels of serum IgG to Shigella lipopolysaccharide: re-analysis of Shigella vaccine trials data. Clinical Microbiology and Infection. 2022;29(3):366-71.
  7. Bassal R, Keinan-Boker L, Cohen D, Mendelson E, Lustig Y, Indenbaum V. Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020–July 2021. Vaccines. 2022;10(10):1663.
  8. Avni Biron I, Maayan Y, Mishael T, Hadar E, Neeman M, Plitman Mayo R, Sela HY, Yagel S, Goldenberg R, Ben Ya’acov A, Grisaru Granovsky S, Ollech JE, Edelman-Klapper H, Rabinowitz KM, Pauker MH, Yanai H, Goren S, Cohen D, Dotan I, Bar-Gil Shitrit A. SARS-CoV-2 IgG Antibody Levels in Women with IBD Vaccinated during Pregnancy. Vaccines. 2022;10(11):1833
  9. Mathur S, Bardenstein S, Cohen D, Banai M. Serum PCR Diagnosis of Brucella melitensis Infection in Rev. 1 Vaccinated Sheep. Microbiology Research. 2022;14(1):21-33.
  10. Donkor ES, Muhsen K, Johnson SAM, Kotey FCN, Dayie NTKD, Tetteh-Quarcoo PB, Tette EMA, Osei M-M, Egyir B, Nii-Trebi NI, Owusu-Okyere G, Owusu-Ofori A, Amir Y, Perlman S, Lopes PH, Mfodwo A, Gordon NC, Gresham L, Smolinski M, Cohen D. Multicenter Surveillance of Antimicrobial Resistance among Gram-Negative Bacteria Isolated from Bloodstream Infections in Ghana. Antibiotics. 2023;12(2):255.
  11. Cohen D, Izak M, Stoyanov E, Mandelboim M, Perlman S, Amir Y, Goren S, Bialik A, Kliker L, Atari N, Yishai R, Zaide Y, Marcus H, Madar-Balakirski N, Israely T, Paran N, Zimhony O, Shinar E, Maor Y, Muhsen K. Predictors of reinfection with pre-Omicron and Omicron variants of concern among individuals who recovered from COVID-19 in the first year of the pandemic. International Journal of Infectious Diseases. 2023;132:72-9.
  12. Miti S, Chilyabanyama ON, Chisenga CC, Chibuye M, Bosomprah S, Mumba C, Chitondo S, Siziya S, Cohen D, Chilengi R, Simuyandi M. Sensitivity and predictive value of dysentery in diagnosing shigellosis among under five children in Zambia. Plos one. 2023;18(2):e0279012.
  13. Meron-Sudai S, Asato V, Adler A, Bialik A, Goren S, Ariel-Cohen O, Reizis A, Mulard LA, Phalipon A, Cohen D. A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults. npj Vaccines. 2023;8(1):35.
  14. Bassal R, Davidovich-Cohen M, Yakunin E, Rokney A, Ken-Dror S, Strauss M, Wolf T, Sagi O, Amit S, Moran-Gilad J, Treygerman O, Karyo R, Keinan-Boker L, Cohen D. Trends in the Epidemiology of Non-Typhoidal Salmonellosis in Israel between 2010 and 2021. International Journal of Environmental Research and Public Health. 2023:24;20(9):5626.
  15. Lapidot Y, Maya M, Reshef L, Cohen D, Ornoy A, Gophna U, Muhsen K. Relationships of the gut microbiome with cognitive development among healthy school-age children. Frontiers in Pediatrics. 2023;11:1198792.
  16. Mazaba ML, Bosomprah S, Cohen D, Monze M, Siziya S. Estimated incidence and transmission intensity of rubella infection in Zambia pre-vaccine era 2005–2016. Epidemiology & Infection. 2023;151:e9.
  17. Maor Y, Shinar E, Izak M, Rahav G, Brosh-Nissimov T, Kessler A, Rahimi-Levene N, Benin-Goren O, Cohen D, Zohar I, Alagem N, Castro S, Zimhony O. A Randomized Controlled Study Assessing Convalescent Immunoglobulins vs Convalescent Plasma for Hospitalized Patients With Coronavirus 2019. Clinical Infectious Diseases. 2023:ciad305.
  18. Edelman-Klapper H, Rabinowitz KM, Zittan E, Shitrit AB, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Broitman Y, Ben Zvi H, Perets TT, Eliakim R, Barkan R, Goren S, Cohen D, Dotan I. Serologic Response and Safety after a Third Dose of the COVID-19 BNT162b2 Vaccine in Patients with Inflammatory Bowel Diseases. Vaccines. 2023;20;11(7):1263.
  19. Toapanta FR, Hu J, Meron-Sudai S, Mulard LA, Phalipon A, Cohen D, Sztein MB. Further characterization of Shigella-specific (memory) B cells induced in healthy volunteer recipients of SF2a-TT15, a Shigella flexneri 2a synthetic glycan-based vaccine candidate. Front Immunol. 2023 Oct 31;14:1291664.
  20. Asato V, Bassal R, Meron-Sudai S, Goren S, Keinan-Boker L, MacLennan CA, Cohen D. IgG Serum Antibodies to Shigella sonnei Lipopolysaccharide Are Inversely Associated with the Incidence of Culture-Proven S. sonnei Shigellosis in Israeli Children and Adolescents. Vaccines. 2024; 12(3):239.
  21. Cohen D, Treygerman O, Ken-Dror S, Sagi O, Strauss M, Parizade M, Goren S, Ezernitchi AV, Rokney A, Keinan-Boker L, Bassal R. Twenty-five years of sentinel laboratory-based surveillance of shigellosis in a high-income country endemic for the disease, Israel, 1998 to 2022. Euro Surveill. 2024 Aug;29(31):2400022.
  22. Amir Y, Omar M, Adler A, Abu-Moch S, Donkor ES, Cohen D, Muhsen K. The prevalence of antimicrobial drug resistance of non-typhoidal Salmonella in human infections in sub-Saharan Africa: a systematic review and meta-analysis. Expert Rev Anti Infect Ther. 2024 Sep;22(9):761-774.
  23. Omar M, Kassem E, Anis E, Abu-Jabal R, Mwassi B, Shulman L, Cohen D, Muhsen K. Factors associated with antibiotic use in children hospitalized for acute viral gastroenteritis and the relation to rotavirus vaccination. Hum Vaccin Immunother. 2024 Dec 31;20(1):2396707.
  24. Omar M, Kassem E, Abu-Jabal R, Mwassi B, Cohen D, Muhsen K. Characterization of Antibiotic Treatment among Children Aged 0-59 Months Hospitalized for Acute Bacterial Gastroenteritis in Israel. Antibiotics (Basel). 2024 Jan 8;13(1):64.

 

 Reviews

Cohen D, Meron-Sudai S, Bialik A, Asato V, Ashkenazi S. Detoxified O-Specific Polysaccharide (O-SP)–Protein Conjugates: Emerging Approach in the Shigella Vaccine Development Scene. Vaccines. 2022;10(5):675.

 

 

 

Clinical Study Protocols

"A Phase I Dose Escalation Study to Assess the Safety and Immunogenicity of the SF2a-TT15 Conjugate Vaccine against S. flexneri 2a in Healthy Adult Volunteers." 2015. Click here to view. 

אוניברסיטת תל אביב עושה כל מאמץ לכבד זכויות יוצרים. אם בבעלותך זכויות יוצרים בתכנים שנמצאים פה ו/או השימוש שנעשה בתכנים אלה לדעתך מפר זכויות
שנעשה בתכנים אלה לדעתך מפר זכויות נא לפנות בהקדם לכתובת שכאן >>
אוניברסיטת תל-אביב, רחוב חיים לבנון 30, 6997801.